Replies

https://patents.justia.com/inventor/robert-w-malone

Some of his RNA vaccine enabling patents

Patents by Inventor Robert W. Malone
Robert W. Malone has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

Compounds and methods for enhancing delivery of free polynucleotide
Publication number: 20040009947
Abstract: The discovery of simple, nontoxic, and pharmaceutically defined methods for genetic modification of cells and tissues would enable development of a variety of molecular medicines. “Free”, ‘direct’, or ‘naked’ polynucleotide administration is a simple, apparently safe, and pharmaceutically defined polynucleotide delivery method. Murine, macaque, and clinical human experiments have demonstrated transfection of various tissues, such as respiratory tissues, after direct application of ‘free’ polynucleotide. However, direct DNA transfection is relatively inefficient in comparison to many transduction systems. The invention herein is directed to transfection enhancing agents which augment the transfection activity of ‘free’ polynucleotide, thereby facilitating the development of simple and safe alternatives to tissue transfection, more particularly respiratory tissue transfection.
Type: Application
Filed: May 27, 2003
Publication date: January 15, 2004
Inventors: Robert W. Malone, Jill G. Malone

DNA vaccines for eliciting a mucosal immune response
Patent number: 6110898
Abstract: The invention consists of a method for inducing production of a mucosal immune response in a host by administration of an antigen-encoding polynucleotide preparation, comprising DNA or RNA encoding an antigenic epitope to a mucosal inductor site in the mucosal tissue of the host. Naked DNA may be administered directly to mucosa, for instance in saline drops, or in a recombinant gene expression vector. Preferably, the recombinant gene expression vectors are not capable of replication or dessimination. The invention also includes the use of live viral vaccines wherein the viruses include immunostimulatory polynucleotides of the invention. According to a preferred method of the invention, a target protein antigen is administered through its expression by a recombinant gene expression vector.
Type: Grant
Filed: May 23, 1997
Date of Patent: August 29, 2000
Assignee: University of Maryland, Baltimore
Inventors: Robert W. Malone, Jill G. Malone

Formulations and methods for generating active cytofectin: polynucleotide transfection complexes
Patent number: 5925623
Abstract: In the generation of cytofectin:polynucleotide complexes for transfection of cells, formulations, counterions, and reaction conditions for maximizing the transfection include using a cationic amine compound that has the general structure: ##STR1## wherein R.sub.4 and R.sub.5 are a pair of same or different lipoyl moieties selected from a group consisting of an alkyl, alkenyl, alkynyl, alkanoyl, alkenoyl, or alkynoyl groups and for R.sub.1, R.sub.2, and R.sub.3 at least two are hydroxylated, ether containing, or acyloxy containing alkyl, alkenyl, or alkynyl groups or at least one amine bonded halogen containing moiety selected from a group consisting of a halogenated alkyl, alkenyl, or alkynyl group or a mixture of at least one halogen containing moiety selected from a group consisting of a halogenated alkyl, alkenyl, or alkynyl group and at least one hydroxylated, ether containing, or acyloxy containing alkyl, alkenyl, or alkynyl group, and X.sup.- is an oxyanion or halide counterion.
Type: Grant
Filed: July 15, 1996
Date of Patent: July 20, 1999
Assignee: The Regents of the University of California
Inventors: Michael H. Nantz, Michael J. Bennett, Rajiv P. Balasubramaniam, Alfred M. Aberle, Robert W. Malone

Cationic transport reagents
Patent number: 5892071
Abstract: For use in transporting biologically active species into and through membrane barriers, a symmetrical cationic diamine compound having the general structure ##STR1## wherein m=1-10; R.sub.1 is a hydrogen, an alkyl group, an alkenyl group, a hydroxylated alkyl or alkenyl group, or an ether containing alkyl or alkenyl group; R.sub.2 is an alkyl group, an alkenyl group, or an alkyl or alkenyl containing acyl group; R.sub.3 is a hydrogen, an alkyl group, an alkenyl group, a hydroxylated alkyl or alkenyl group, or an ether containing alkyl or alkenyl group; R.sub.4 is a hydrogen, an alkyl group, an alkenyl group, a hydroxylated alkyl or alkenyl group, or an ether containing alkyl or alkenyl group; and X.sup.- is an anion.
Type: Grant
Filed: September 15, 1995
Date of Patent: April 6, 1999
Assignee: The Reagents of The University of California
Inventors: Michael H. Nantz, Michael J. Bennett, Robert W. Malone

——————
Now run and hide, troll.